Substance use and HIV disease progression in the HAART era: Implications for the primary prevention of HIV

Life Sciences

Volumn 88, Issue 21-22, 2011, Pages 940-947

  Carrico, Adam W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adherence; Antiretroviral; Cocaine; Disease progression; Highly active; HIV AIDS; Injection drug use; Methamphetamine; Mortality; Norepinephrine; Substance use; Survival

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; ADENYLATE CYCLASE; ANTIRETROVIRUS AGENT; CANNABIS; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; COCAINE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; DIAMORPHINE; GAMMA INTERFERON; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 10; METHAMPHETAMINE; NEOPTERIN; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NORADRENALIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOL ABUSE; AUTONOMIC NERVOUS SYSTEM FUNCTION; BACTERIAL PNEUMONIA; CD4 LYMPHOCYTE COUNT; CIGARETTE SMOKING; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ABUSE; DRUG MONITORING; DRUG RESPONSE; DRUG UTILIZATION; FOLLOW UP; HEPATITIS C; HIGH RISK BEHAVIOR; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV TEST; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; LYMPHOCYTE MEMBRANE; MACROPHAGE; MALE HOMOSEXUAL; MEDLINE; MIXED INFECTION; MORTALITY; MULTICENTER STUDY (TOPIC); NONHUMAN; NORADRENALIN RELEASE; PATIENT COMPLIANCE; PREDICTION; PROTEIN BLOOD LEVEL; PSYCHOPHYSIOLOGY; REVIEW; SEX DIFFERENCE; SEXUAL BEHAVIOR; SIGNAL TRANSDUCTION; SIMIAN IMMUNODEFICIENCY VIRUS; SMOKING; SUBSTANCE ABUSE; SYSTEMATIC REVIEW; T LYMPHOCYTE; TUBERCULOSIS; UPREGULATION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AUTONOMIC NERVOUS SYSTEM; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; MEDICATION ADHERENCE; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; SUBSTANCE-RELATED DISORDERS; VIRAL LOAD;

EID: 79956195241     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.10.002     Document Type: Review

References (76)

1. K. Anastos, M.F. Schneider, S.J. Gange, H. Minkoff, R.M. Greenblatt, J. Feldman, A. Levine, R. Delapenha, and M. Cohen The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretroviral therapy in women J Acquir Immune Defic Syndr 39 2005 537 544 (Pubitemid 41098467)
2. J.H. Arnsten, P.A. Demas, R.W. Grant, M.N. Gourevitch, H. Farzadegan, A.A. Howard, and E.E. Schoenbaum Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users J Gen Intern Med 17 2002 377 381 (Pubitemid 34626108)
3. M.K. Baum, C. Rafie, S. Lai, S. Sales, B. Page, and A. Campa Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users J Acquir Immune Defic Syndr 50 2009 93 99
4. E.G. Bing, M.A. Burnam, D. Longshore, J.A. Fleishman, C.D. Sherbourne, A.S. London, B.J. Turner, F. Eggan, R. Beckman, B. Vitiello, S.C. Morton, M. Orlando, S.A. Bozzette, L. Ortiz-Barron, and M. Shapiro Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States Arch Gen Psychiatry 58 2001 721 728 (Pubitemid 32717795)
5. G.A. Cabral Drugs of abuse, immune modulation, and AIDS J Neuroimmune Pharmacol 1 2006 280 295 (Pubitemid 44244133)
6. A.W. Carrico, M.O. Johnson, J.T. Moskowitz, T.B. Neilands, S.F. Morin, E.D. Charlebois, W.T. Steward, R.H. Remien, F.L. Wong, M.J. Rotheram-Borus, M.A. Lightfoot, and M.A. Chesney Affect regulation, stimulant use, and viral load among HIV-positive persons on anti-retroviral therapy Psychosom Med 69 2007 785 792 (Pubitemid 350287486)
7. A.W. Carrico, M.O. Johnson, S.F. Morin, R.H. Remien, E.D. Riley, F.M. Hecht, and D. Fuchs Stimulant use is associated with immune activation and depleted tryptophan among HIV-positive persons on anti-retroviral therapy Brain Behav Immun 22 2008 1257 1262
8. D.D. Celentano, D. Vlahov, S. Cohn, V.M. Shadle, O. Obasanjo, and R.D. Moore S elf-reported antiretroviral therapy in injection drug users J Am Med Assoc 280 1998 544 546
9. S.W. Cole Psychosocial influences on HIV-1 disease progression: neural, endocrine, and virologic mechanisms Psychosom Med 70 2008 562 568
10. S.W. Cole, Y.D. Korin, J.L. Fahey, and J.A. Zack Norepinephrine accelerates HIV replication via protein kinase A-dependent effects on cytokine production J Immunol 161 1998 610 616 (Pubitemid 28323521)
11. S.W. Cole, B.D. Jamieson, and J.A. Zack cAMP up-regulates cell surface expression of lymphocyte CXCR4: implications for chemotaxis and HIV-1 infection J Immunol 162 1999 1392 1400 (Pubitemid 29307010)
12. S.W. Cole, B.D. Naliboff, M.E. Kemeny, M.P. Griswold, J.L. Fahey, and J.A. Zack Impaired response to HAART in HIV-infected individuals with high autonomic nervous system activity Proc Natl Acad Sci 98 2001 12695 12700 (Pubitemid 33020008)
13. S.W. Cole, M.E. Kemeny, J.L. Fahey, J.A. Zack, and B.D. Naliboff Psychological risk factors for HIV pathogenesis: mediation by the autonomic nervous system Biol Psychiatry 54 2003 1444 1456 (Pubitemid 37522170)
14. G.N. Colfax, E. Vittinghoff, R. Grant, P. Lum, G. Spotts, and F.M. Hecht Frequent methamphetamine use is associated with primary non-nucleoside reverse transcriptase inhibitor resistance AIDS 21 2007 239 241 (Pubitemid 46036934)
15. G. Colfax, G.M. Santos, P. Chu, E. Vittinghoff, A. Pluddemann, S. Kumar, and C. Hart Amphetamine-group substances and HIV Lancet 376 9739 2010 458 474
16. A. Collado-Hidalgo, C. Sung, and S. Cole Adrenergic inhibition of innate anti-viral response: PKA blockade of Type I interferon gene transcription mediates catecholamine support for HIV-1 replication Brain Behav Immun 20 2006 552 563 (Pubitemid 44528951)
17. J.A. Cook, J.K. Burke-Miller, M.H. Cohen, R.L. Cook, D. Vlahov, T.E. Wilson, E.T. Golub, R.M. Schwartz, A.A. Howard, C. Ponath, M.W. Plankey, A.M. Levine, and D.D. Grey Crack cocaine, disease progression, and mortality in a multicenter cohort of HIV-1 positive women AIDS 22 2008 1355 1363
18. M. Das, P.L. Chu, G.M. Santos, S. Scheer, E. Vittinghoff, W. McFarland, and G.N. Colfax Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco Public Libr Sci One 5 2010 e11068
19. D.C. Des Jarlais, and S. Semaan HIV prevention for injecting drug users: the first 25 years and counting Psychosom Med 70 2008 606 611
20. C.W. Dieffenbach, and A.S. Fauci Universal voluntary testing and treatment for prevention of HIV transmission J Am Med Assoc 301 2009 2380 2382
21. R.M. Donahoe, and D. Vlahov Opiates as potential cofactors in progression of HIV-1 infections to AIDS J Neuroimmunol 83 1998 77 87 (Pubitemid 28280954)
22. J. Dunbar-Jacob, E.A. Schlenk, and D. Caruthers Adherence in the management of chronic disorders A.J. Christensen, M.H. Antoni, Chronic Physical Disorders: Behavioral Medicine's Perspective 2002 Blackwell Publishers Malden, MA 69 82
23. M. Egger, M. May, G. Chene, A.N. Phillips, B. Ledergerber, F. Dabis, D. Costagliola, A. D'Arminio Monforte, F. de Wolf, P. Reiss, J.D. Lundgren, A.C. Justice, S. Staszewski, C. Leport, R.S. Hogg, C.A. Sabin, M.J. Gill, B. Salzberger, and J.A.C. Sterne Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies Lancet 360 2002 119 129 (Pubitemid 34786200)
24. R.J. Ellis, M.E. Childers, M. Cherner, D. Lazzaretto, S. Letendre, and I. Grant Increased human immunodeficiency virus loads in active methamphetamine users are explained by reduced effectiveness of antiretroviral therapy J Infect Dis 188 2003 1820 1826 (Pubitemid 38064866)
25. D.L. Felten, S. Felten, S.L. Carlson, J.A. Olschowka, and S. Livnat Noradrenergic peptidergic innervation lymphoid tissue J Immunol 135 1985 755s 765s (Pubitemid 16229425)
26. M. Gandi, N. Ameli, P. Bacchetti, S.J. Gange, K. Anastos, A. Levine, C.L. Hyman, M. Cohen, Y. Huang, and R.M. Greenblatt Protease inhibitor levels in hair strongly predict virologic response to treatment AIDS 20 2009 471 478
27. P.M. Gorbach, L.N. Drumright, M. Javanbakht, S.L. Pond, C.H. Woelk, E.S. Daar, and S.J. Little Antiretroviral drug resistance and risk behavior among recently HIV-infected men who have sex with men J Acquir Immune Defic Syndr 47 2008 639 643 (Pubitemid 351442022)
28. C. Gore-Felton, and C. Koopman Behavioral mediation of the relationship between psychosocial factors and HIV disease progression Psychosom Med 70 2008 569 574
29. R.M. Granich, C.F. Gilks, C. Dye, K.M. De Cock, and B.G. Williams Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model Lancet 373 2009 48 57
30. A. Grigoryan, H.I. Hall, T. Durant, and X. Wei Lat HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US states, 1996-2004 PLoS ONE 4 2009 e4445
31. R.A. Hahn, I.M. Onorato, T.S. Jones, and J. Dougherty Prevalence of HIV infection among intravenous drug users in the United States J Am Med Assoc 261 1989 2677 2684 (Pubitemid 19127964)
32. H.I. Hall, K. McDavid, Q. Ling, and A. Sloggett Determinants of progression to AIDS or death after HIV diagnosis, United States, 1996 to 2001 Ann Epidemiol 16 2006 824 833 (Pubitemid 44780980)
33. C.H. Hinkin, T.R. Barclay, S.A. Castellon, A.J. Levine, R.S. Durvasula, S.D. Marion, H.F. Myers, and D. Longshore Drug use and medication adherence among HIV-1 infected individuals AIDS Behav 11 2007 185 194
34. A.A. Howard, R.S. Klein, E.E. Schoenbaum, and M.N. Gourevitch Crack cocaine use and other risk factors for tuberculin positivity in drug users Clin Infect Dis 35 2002 1183 1190 (Pubitemid 35314518)
35. P.W. Hunt, S.G. Deeks, D.R. Bangsberg, A. Moss, E. Sinclair, T. Liegler, M. Bates, G. Tsao, H. Lampiris, R. Hoh, and J.N. Martin The independent effect of drug resistance on T cell activation in HIV infection AIDS 20 2006 691 699 (Pubitemid 43884296)
36. M.R. Irwin, L. Olmos, M. Wang, E.M. Valladares, S.J. Motivala, T. Fong, T. Newton, A. Butch, R. Olmstead, and S.W. Cole Cocaine dependence and acute cocaine induce decreases of monocyte proinflammatory cytokine expression across the diurnal period: autonomic mechanisms J Pharmacol Exp Ther 320 2007 507 515 (Pubitemid 46151073)
37. C. Junghans, N. Low, P. Chan, A. Witschi, P. Vernazza, and M. Egger Uniform risk of clinical progression despite differences in utilization of highly active antiretroviral therapy: Swiss HIV Cohort Study AIDS 13 1999 2547 2554 (Pubitemid 30038033)
38. S.C. Kalichman Co-occurrence of treatment nonadherence and continued HIV transmission risk behaviors: implications for positive prevention interventions Psychosom Med 70 2008 593 597
39. F. Kapadia, J.A. Cook, M.H. Cohen, N. Sohler, A. Kovacs, R.M. Greenblatt, I. Choudhary, and D. Vlahov The relationship between non-injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use Addiction 100 2005 990 1002 (Pubitemid 40897294)
40. F. Kapadia, D. Vlahov, R.M. Donahoe, and G. Friedlan The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations Clin Infect Dis 41 2005 1027 1034 (Pubitemid 41368228)
41. N. Klimas, A.O. Koneru, and M.A. Fletcher Overview of HIV Psychosom Med 70 2008 523 530
42. B. Kobilka Adrenergic receptors as models for G protein-coupled receptors Annu Rev Neurosci 15 1992 87 114
43. B.A. Koblin, M.J. Husnik, G. Colfax, Y. Huang, M. Madison, K. Mayer, P.J. Barresi, T.J. Coates, M.A. Chesney, and S. Buchbinder Risk factors for HIV infection among men who have sex with men AIDS 20 2006 731 739 (Pubitemid 43884301)
44. H. Liang, X. Wang, H. Chen, L. Song, L. Ye, S.H. Wang, Y.J. Wang, L. Zhou, and W.Z. Ho Methamphetamine enhances HIV infection of macrophages Am J Pathol 172 6 2008 1617 1624 (Pubitemid 351793354)
45. M.M. Llabre, K.E. Weaver, R.E. Duran, M.H. Antoni, S. McPherson-Baker, and N. Schneiderman A measurement model of medication adherence to highly active antiretroviral therapy and its relation to viral load in HIV-positive adults AIDS Patient Care STDs 20 2006 701 711 (Pubitemid 46141369)
46. M.C. Lopez, L.L. Colombo, D.S. Huang, Y. Wang, and R.R. Watson Modification of thymic cell subsets induced by long-term cocaine administration during a murine retroviral infection producing AIDS Clin Immunol Immunopathol 65 1992 45 52
47. G.M. Lucas, K.A. Gebo, R.E. Chaisson, and R.D. Moore Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic AIDS 16 2002 767 774 (Pubitemid 34274467)
48. G.M. Lucas, M. Griswold, K.A. Gebo, J. Keruly, R.E. Chaisson, and R.D. Moore Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy Am J Epidemiol 163 2006 412 420
49. T. Makisumi, K. Yoshida, T. Watanabe, N. Tan, N. Murakami, and A. Morimoto Sympatho-adrenal involvement in methamphetamine-induced hyperthermia through skeletal muscle hypermetabolism Eur J Pharmacol 363 1998 107 112 (Pubitemid 29057753)
50. M. Malta, F.I. Bastos, C.M.F.P. da Silva, G.F.M. Pereira, F.F.A. Lucena, M.G.P. Fonseca, and S.A. Strathdee Differential survival benefit of universal HAART access in Brazil: A nation-wide comparison of injecting drug users versus men who have sex with men J Acquir Immune Defic Syndr 52 2009 629 635
51. K.H. Mayer, J.W. Hogan, D. Smith, R.S. Klein, P. Schuman, J.B. Margolick, C. Korkontzelou, H. Farzedegan, D. Vlahov, and C.C. Carpenter Clinical and immunologic progression in HIV-infected US women before and after the introduction of highly active antiretroviral therapy J Acquir Immune Defic Syndr 33 2003 614 624 (Pubitemid 36975850)
52. A. Mocroft, S. Madge, A.M. Johnson, A. Lazzarin, N. Clumeck, F.D. Goebel, J.P. Viard, J. Gatell, A. Blaxhult, and J.D. Lundgren A comparison of exposure groups in the EuroSIDA study: starting highly active antiretroviral therapy (HAART), response to HAART, and survival J Acquir Immune Defic Syndr 22 1999 369 378 (Pubitemid 30030429)
53. J.S. Montaner, V.D. Lima, R. Barrios, B. Yip, E. Wood, T. Kerr, K. Shannon, P.R. Harrigan, R.S. Hogg, P. Daly, and P. Kendall Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Can population based study Lancet 376 2010 532 539
54. R.D. Moore, J.C. Keruly, and R.E. Chaisson Differences in HIV disease progression by injecting drug use in HIV-infected persons in care J Acquir Immune Defic Syndr 35 2004 46 51 (Pubitemid 38044781)
55. S.F. Morin, J.J. Myers, S.B. Shade, K. Koester, A. Maiorana, and C.D. Rose Predicting HIV transmission risk among HIV-infected patients seen in clinical settings AIDS Behav 11 2007 S6 S16
56. D.M. Nance, and V.M. Sanders Autonomic innervation and regulation of the immune system (1987-2007) Brain Behav Immun 21 2007 736 745 (Pubitemid 47002215)
57. E.A. Operskalski, W.J. Mack, H.D. Strickler, A.L. French, M. Augenbraun, P.C. Tien, M.C. Villacres, L.Y. Spencer, M. Degiacomo, and A. Kovacs Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women J Clin Virol 41 2008 255 263
58. A. Palepu, M. Tyndall, B. Yip, M.V. O'Shaughnessy, R.S. Hogg, and J.S. Montaner Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use J Acquir Immune Defic Syndr 32 2003 522 526 (Pubitemid 36423124)
59. C.R. Pearson, J.M. Simoni, P. Hoff, A.E. Kurth, and D.P. Martin Assessing antiretroviral adherence via electronic drug monitoring and self-report: an examination of key methodological issues AIDS Behav 11 2007 161 173
60. T. Pellegrino, and B.M. Bayer In vivo effects of cocaine on immune cell function J Neuroimmunol 83 1998 139 147 (Pubitemid 28280960)
61. S. Perez-Hoyos, J. del Amo, R. Muga, J. del Romero, P. Garcia de Olalla, R. Guerrero, and I. Hernandez Aguado Effectiveness highly active antiretroviral therapy Span cohorts HIV seroconverters differences by transmission category AIDS 17 2003 353 359 (Pubitemid 36223260)
62. K. Porter, A. Babiker, K. Bhaskaran, J. Darbyshire, P. Pezzotti, K. Porter, A.S. Walker CASCADE Collaboration Determinants of survival following HIV-1 seroconversion after the introduction of HAART Lancet 362 2003 1267 1273
63. K.E. Poundstone, R.E. Chaisson, and R.D. Moore Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy AIDS 15 2001 1115 1123 (Pubitemid 32549862)
64. T.C. Quinn, M.J. Wawer, N. Sewankambo, D. Serwadd, C. Li, F. Wabwire-Mangen, M.O. Meehan, T. Lutalo, and R.H. Gray Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group N Engl J Med 342 2000 921 929 (Pubitemid 30177052)
65. L.S. Robison, A.O. Westfall, M.J. Mugavero, M.C. Kempf, S.R. Cole, J.J. Allison, J.H. Willig, J.L. Raper, C.M. Wilcox, and M.S. Saag Short-term discontinuation of HAART regimens more common in vulnerable patient populations AIDS Res Hum Retroviruses 24 2008 1347 1355
66. M.A. Rodriguez-Arenas, I. Jarrin, J. Del Amo, J.A. Iribarren, S. Moreno, P. Viciana, A. Pena, J.L.G. Sirvent, F. Vidal, J. Lacruz, F. Gutierrez, J.A. Oteo, R. Asencio, J. Castilla, and S. Perez Hoyos Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain AIDS Res Hum Retroviruses 8 2006 715 723 (Pubitemid 44734997)
67. V.M. Sanders, and A. Kavelaars Adrenergic regulation of immunity R. Ader, Psychoneuroimmunology 4th Ed. 2007 Elsevier Academic Press Burlington MA 63 83
68. J.M. Simoni, A.E. Kurth, C.R. Pearson, D.W. Pantalone, J.O. Merrill, and P.A. Frick Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management AIDS Behav 10 2006 227 245
69. E.K. Sloan, R.P. Tarara, J.P. Capitanio, and S.W. Cole Enhanced replication of simian immunodeficiency virus adjacent to catecholaminergic varicosities in primate lymph nodes J Virol 80 2006 4326 4335
70. R. Stall The prevention of HIV infection associated with drug and alcohol use during sexual activity Adv Alcohol Subst Abuse 7 1987 73 88
71. L.E. Thorpe, M. Frederick, J. Pitt, I. Cheng, D.H. Watts, S. Buschur, K. Green, C. Zorrilla, S.H. Landesman, and R.C. Hershow Effect of hard-drug use on CD4 cell percentage, HIV RNA level, and progression to AIDS-defining class C events among HIV-infected women J Acquir Immune Defic Syndr 37 2004 1423 1430 (Pubitemid 39435057)
72. M. Tornatore, C.V. Goncalves, R.A. Mendoza-Sassi, J.M. Silveira, N.E. D'Avila, C.G. Maas, M.S. Bianch, E.M. Pinheiro, E.S. Machado, M.A. Soares, and A.M. Martinez HIV-1 vertical transmission in Rio Grande, South Brazil Int J STD AIDS 21 2010 351 355
73. M.P. Webber, E.E. Schoenbaum, M.N. Gourevitch, D. Buono, and R.S. Klein A prospective study of HIV disease progression in female and male drug users AIDS 13 1999 257 262 (Pubitemid 29050414)
74. W. Wong, J.K. Chaw, C.K. Kent, and J.D. Klausner Risk factors for early syphilis among gay and bisexual men seen in an STD clinic: San Francisco, 2002-2003 Sex Transm Dis 32 2005 458 463 (Pubitemid 40875384)
75. E. Wood, J.S. Montaner, B. Yip, M.W. Tyndall, M.T. Schechter, M.V. O'Shaughnessy, and R.S. Hogg Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users Can Med Assoc J 169 2003 656 661 (Pubitemid 37266973)
76. E. Wood, R.S. Hogg, V.D. Lima, T. Kerr, B. Yip, B.D.L. Marshall, and J.S.G. Montaner Highly active antiretroviral therapy and survival in HIV-infected injection drug users J Am Med Assoc 300 2008 550 554